Benzinga

Benzinga

Benzinga

miércoles, septiembre 02

Abbott Laboratories

ABTNYSE
Trade with Public
Trade with Public
$111.02
2.091.92%
Últ. Act.: Sep 2, 10:24 AM
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadDividendosCompararOpcionesInforme de acciones

Abbott Laboratories Analyst Price Targets

Wall Street analyst price targets and consensus rating for Abbott Laboratories (ABT).

Price Target Range — 8 Quarters

Analyst Consensus — 22 Analysts

21Buy
1Hold
Consensus RatingBuy# Analysts22Avg. Consensus PT$129Upside to Avg. PT+16.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 21, 2026TD CowenJoshua JenningsPT RaiseBuy$115→$135
Aug 14, 2026CitigroupJoanne WuenschPT RaiseBuy$112→$125
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wolfe Research Upgrades Abbott Laboratories to Outperform, Announces $130 Price Target

Wolfe Research analyst Mike Polark upgrades Abbott Laboratories (NYSE:ABT) from Peer Perform to Outperform and announces $130 price target.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Abbott Laboratories, Lowers Price Target to $125

UBS analyst Patrick Wood maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $125.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Abbott Laboratories, Raises Price Target to $112

Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and raises the price target from $108 to $112.
Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Abbott Laboratories, Raises Price Target to $118

Piper Sandler analyst Adam Maeder reiterates Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $115 to $118.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Abbott Laboratories, Raises Price Target to $120

JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $110 to $120.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $112

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $109 to $112.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved